Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma.
Best T; Li D; Skol AD; Kirchhoff T; Jackson SA; Yasui Y; Bhatia S; Strong LC; Domchek SM; Nathanson KL; Olopade OI; Huang RS; Mack TM; Conti DV; Offit K; Cozen W; Robison LL; Onel K; Nature Medicine, 2011, vol. 17, issue 8, p 941, ISSN 1546170x. ISBN 1546170x.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef